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The psychostimulant methylphenidate (MPH) is the prima y drug treatment for attention 
deficit hyperactivity disorder (ADHD) in children. MPH is well known to acutely block the 
dopamine (DAT) and noradrenaline (NET) transporters. Its effect on additional 
catecholamine targets is however less known. This study was aimed at comparing the effects 
of acute (2 mg/kg, i.p.) and chronic (2 mg/kg twice daily for 2 weeks) MPH treatment to 
young rats on key catecholamine protein targets in brain regions implicated in the symptoms 
and treatment of ADHD. For this purpose, the density of DAT, NET, the vesicular 
monoamine transporter 2 (VMAT2), the rate limiting enzyme for catecholamine synthesis 
tyrosine hydroxylase (TH) and the dopamine D1 receptor were measured in frontal (FC), 
parietal cortex (PCx) and the dorsal (DS) and ventral (VS) striatum. The data demonstrate 
that the effects of MPH depend on duration of treatment and brain region investigated. With 
the exception of DAT in the VS our results indicate that chronic but not acute administration 
of MPH increases levels of DAT, NET, TH, VMAT2 and D1. These effects were further 
more prominent in the VS over DS and in the PCx compared to the FC. In addition, chronic 
MPH enhanced DAT levels in the left DS but not in right side. To summarize, this study 
shows new evidence that chronic MPH to young rats preferentially alters catecholamine 
targets in PCx and VS over DS and FC. The effect of hronic MPH to increase levels of 
DAT, NET and VMAT2 suggests that the drug might long-term loose some of its acute 
action to increase extracellular levels of dopamine a d noradrenaline. In conclusion, these 
findings provide novel insights into the mechanism of action by MPH in the treatment of 




















Attention deficit hyperactivity disorder (ADHD) is a prevalent childhood neuropsychiatric 
disorder and twin studies have established that there is a strong genetic component of the 
condition (Shastry, 2004). Specifically, the latrophilin 3 (LPHN3) gene has been associated 
with ADHD genetic susceptibility and the pharmacogenetics of the condition (Labbe et al., 
2012);Bruxel et al., 2015). The key symptoms of ADHD are inattention, impulsivity, 
hyperactivity, and deficits in catecholamines (i.e. dopamine and noradrenaline) have often 
been associated with these symptoms of the disorder (Volkow et al., 2007;Del Campo et al., 
2011). Acute administration of the psychostimulant methylphenidate (MPH), which is the 
first-line drug for ADHD, is suggested to increase catecholamine signalling by blocking both 
dopamine (DAT) and noradrenaline (NET) transporters. This has been associated with 
symptom improvements in young and adolescent individuals diagnosed with ADHD (Vles et 
al., 2003;Rosa-Neto et al., 2005). However, the effcts of chronic MPH treatment on 
catecholamine signalling including, DAT, NET, and other catecholaminergic markers in 
brain areas associated with the symptoms of ADHD are not fully known.   
The underlying reasons for a dysfunctional dopamine and noradrenaline activity in ADHD 
have been suggested to be mediated via altered expression of some key proteins for dopamine 
and noradrenaline neurotransmission including, the rate limiting enzyme tyrosine 
hydroxylase (TH), the catecholamine transporter proteins DAT and NET, as well as the 
vesicular monoamine transporter protein 2 (VMAT2) (Volkow et al., 2007;Volkow et al., 
2009;Calipari et al., 2014). Dopamine regulates corti al and striatal pathways through the 
activation of five distinct receptors, D1-D5 (Beaulieu and Gainetdinov, 2011). Together with 
the transporter proteins (DAT, NET, and VMAT2) and the rate limiting enzyme TH, 
abnormalities of some dopamine receptors have also been implicated in the pathology of 














action on cortical cognitive function has been implicated in the symptoms of ADHD and its 
treatment (Del Campo et al., 2011;Calipari et al., 2014;Narendran et al., 2015).  
Given the role of cortico-striatal networks in cognition and motor behaviour, current 
neurobiological theories of ADHD focus on morphological and functional abnormalities in 
these two major brain networks as they are likely mediating the core symptoms of ADHD 
(Ashtari et al., 2005;Bush, 2011;Castellanos et al., 1996;Semrud-Clikeman et al., 2000). A 
deviation from the common pattern of cerebral lateralisation is also suggested to contribute to 
the symptoms of ADHD including the executive function deficits (Ribases et al., 2009;Liu et 
al., 2013). Indeed, some studies have found increased involvement of the right cerebral 
hemisphere in ADHD. For instance, a previous study observed significant reductions of the 
right caudate and the right cerebral cortex in ADHD patients compared to individuals not 
diagnosed with the condition (Valera et al., 2007). Moreover, functional magnetic resonance 
imaging studies have detected significant under-activ tion of the right frontal and parietal 
cortices in individuals with ADHD during motor and attentional tasks (Rubia et al., 
1999;Vance et al., 2007). However, not much is know about the lateralised effects of 
psychostimulants used in ADHD treatment. 
In this study, we sought to compare the acute and chronic effects of MPH treatment on 
cortical and striatal tissue levels of DAT, NET, VMAT2, TH and D1 receptors in the juvenile 
rat brain. The effect of acute and chronic MPH treatment on striatal DAT levels were further 
compared in the left and right hemispheres.   
2. Materials and Methods 
2.1 Animals and drug treatment 
All animal experiments were conducted in strict accordance with the UK Home Office 














Sprague-Dawley rats at postnatal day (PND) 20 and 35 respectively were purchased from 
Charles River (UK) and were housed six per cage with access to food and water ad libitum. 
The rats were maintained under controlled conditions f light (12 h light/dark cycles) and 
temperature (22-25°C, 45% humidity). The animals were allowed to acclimatise in a five-day 
period prior to the start of the experiments when they were injected intraperitoneally (i.p.) 
with MPH. Following acclimatisation, rats were randomly assigned to acute (single 2 mg/kg 
MPH or 1 ml/kg saline at PND 39) or chronic (2 mg/kg MPH or 1 ml/kg saline; twice daily 
[9am and 5pm] for 2 weeks starting from PND 25) treatment groups. The 2 mg/kg MPH dose 
used in this study has been shown to reach peak plasma levels similar to that observed in 
humans receiving therapeutic MPH doses (Schiffer et al., 2006;Balcioglu et al., 
2009;Kuczenski and Segal, 2005). There were 6 rats per treatment group (n=6 rats/group) and 
the animals were sacrificed 24 h after the last MPH or saline injection (at PND 40). The 
animals were sacrificed via a rapid dislocation of the neck and brain regions corresponding to 
the frontal and parietal cortices, as well as the dorsal and ventral striatum were rapidly 
dissected out on ice and snap-frozen in isopentane on dry ice. The brain samples were 
subsequently stored at -80°C until required for analysis. 
 
2.2 Western blot analysis 
The brain tissues were homogenised in RIPA lysis buffer (Sigma Aldrich, UK) containing 
protease inhibitor at 4°C, as previously described (Quansah et al., 2017b). After 
centrifugation for 10 mins at 13,000 g, total protein concentration was determined via 
Bradford assay (Sigma Aldrich, UK). The protein extrac s were incubated with 
electrophoresis buffer (5% β-2-mercaptoethanol, 20% glycerol, 0.5 M Tris-HCl of pH 6.8, 
0.006% w/v bromophenol blue and 10% sodium dodecyl sulphate) for 3 mins at 90ºC. 20 
µg/µl (~15 µl per lane) of the protein extracts were loaded and separated on 12% sodium 














µm nitrocellulose membrane (GE Healthcare, UK) using a BioRad Trans-blot instrument. All 
blue precision standard markers (BioRad, UK) were loaded in the first lane to aid in 
determining the molecular weight range of the proteins of interest. Following transfer, the 
membranes were blocked with 3% milk in TBST buffer (50 mM Tris; 150 mM NaCl; 0.05% 
Tween-20; pH 7.5) and incubated overnight with the indicated primary antibodies at 4°C. 
The primary antibodies used included: DAT (1:1000 dilution; Santa Cruz, USA), NET 
(1:1000 dilution; OriGene, USA), TH (1:1000 dilution; Abcam, UK), VMAT2 (SLC18A2; 
1:1000 dilution; OriGene, USA) and D1 receptor (1:1000 dilution, Millipore, UK). β-actin 
(1:2000 dilution; Santa Cruz, USA) was used as a loading control in this study. Following 
primary antibody incubation, the membranes were washed three times in TBST buffer and 
incubated for one hour with either an anti-rabbit or anti-mouse secondary antibody (IgG-HRP 
at 1:2000 dilution; Santa Cruz Biotechnology, USA). The membranes were washed three 
times in TBST buffer following secondary antibody incubation and developed with enhanced 
chemiluminescent HRP substrate (Amersham Biosciences, UK) and the signal detected with 
autoradiography film (KodakTM, UK) and then quantified using MCIDTM
 
image analysis 
software (version 7.0). The data was analysed using GraphPad Prism (version 5.0, Graph Pad 
software Inc., La Jolla, CA) and SPSS (version 22, IBM Statistics, Illinois, USA). Statistical 
analyses of all data were performed using separate two- and three-way ANOVA designs with 
the factors ‘drug’ (MPH vs. saline) and ‘duration’ (acute vs. chronic), as well as ‘brain 
hemisphere’ (left vs. right; in the case of DAT protein expression analysis), along with 



















DAT abnormalities have been reported in ADHD, along with increased right hemisphere 
dysfunctions (Rubia et al., 1999;Valera et al., 2007;Del Campo et al., 2011). Indeed, DAT is 
the major target of MPH and other psychostimulants used in ADHD treatment. We therefore 
hypothesized that acute and chronic MPH may induce a modified expression of this 
transporter, possibly in a hemisphere-specific manner. Using the Western blot technique, we 
evaluated DAT expression in the left and right ventral and dorsal striatum following acute 
and chronic MPH treatment. We found that acute MPH 24 hours after the injection increased 
the expression of DAT in the ventral striatum (effect of drug: F(1,20) = 19.1, p < 0.0001; no 
effect of hemisphere: p = 0.09; no hemisphere x drug interaction: p = 0.11), with the effect 
being more prominent in the left side (p < 0.05) rather than the right side (p = 0.06) (Fig. 1). 
Chronic MPH also increased DAT in the ventral striatum (effect of drug: F(1,20) = 21.2, p = 
0.009; no effect of hemisphere: p = 0.13; no hemisphere x drug interaction: p = 0.08), with 
the effect being prominent in both the left (p < 0.05) and right (p < 0.01) sides (Figure 1). In 
the dorsal striatum however acute MPH did not significantly alter DAT density but chronic 
MPH significantly increased dorsal striatal DAT (effect of drug: F(1,20) = 19.1, p < 0.0001; 
effect of hemisphere: p < 0.0001; hemisphere x drug interaction: p < 0.0001). This effect was 
detected in the left dorsal striatum (p < 0.001) but not in the right (Figure 1). In summary, 
acute MPH increased DAT density in the left VS but had no significant effect on DAT in the 
DS. In comparison, chronic MPH increased DAT density in both the left and right VS, as 
well as in the left DS.  
  
Fig. 1  
 
3.2 Chronic but not acute MPH increases NET in PCx and VS 
In addition to dopamine, MPH has also been shown to i crease extracellular noradrenaline 
levels (Kuczenski and Segal, 2002). Thus, we tested whether acute and chronic MPH modify 














and PCx, as well as the VS and DS (no hemisphere effect was evaluated). We found NET 
density to be significantly increased by chronic MPH (but not acute) in the PCx (effect of 
drug: F(1,44) = 18.4, p = 0.02; effect of duration: p = 0.003; duration x drug interaction: p < 
0.001) and the VS (effect of drug: F(1,44) = 10.1, p = 0.04; effect of duration: p = 0.02; 
duration x drug interaction: p = 0.0008) (Fig. 2A). In summary, chronic MPH induced NET 
overexpression in the PCx and VS but not in the FC or DS.  
 
Fig. 2  
 
3.3 Chronic but not acute MPH increases TH and VMAT2 levels 
 
Next, we examined whether acute and chronic MPH alter the density of TH, the rate limiting 
enzyme of dopamine and noradrenaline synthesis. The effect of MPH on TH density was 
investigated in the FC and PCx, as well as in the VS and DS (Fig. 2B). We found that MPH 
enhanced TH expression in the VS (effect of drug: F(1,44) = 6.6, p = 0.02; no effect of 
duration: p = 0.12; no duration x drug interaction: p = 0.51) following chronic (p < 0.05) but 
not the acute treatment. MPH treatment also increased TH levels in the PCx (effect of drug: 
F(1,44) = 4.5, p = 0.01; effect of duration: p = 0.0008; duration x drug interaction: p = 0.02) 
following chronic MPH (p < 0.01) but not acute (Fig. 2B).  
Further, we tested whether M H induces changes in the vesicular transporter VMAT2. Here, 
we found that chronic (but not acute MPH) increased VMAT2 in the FC (effect of drug: 
F(1,44) = 3.7, p = 0.013; effect of duration: p = 0.04; no duration x drug interaction: p = 0.10), 
PCx (effect of drug: F(1,44) = 8.2, p = 0.01; effect of duration: p = 0.0005; duration x drug 
interaction: p = 0.005) and in the VS (effect of drug: F(1,44) = 3.5, p = 0.02; effect of duration: 
p = 0.009; duration x drug interaction: p = 0.003) but not the DS (Fig. 2C). In summary, 
chronic but not acute MPH increased both TH and VMAT2 in the PCx and VS. Chronic but 















3.4 Chronic MPH treatment upregulates D1 receptor expression in PCx and VS 
 
The D1 receptor plays an important role in cognition and some ADHD patients show deficits 
in cognitive functions (Del Campo et al., 2011;Calip r  et al., 2014;Narendran et al., 2015).  
Here, we tested whether MPH treatment influences D1 receptor levels. Chronic MPH (but not 
acute) increased D1 receptor density in the PCx (effect of drug: F(1,44) = 3.7, p = 0.02; effect 
of duration: p = 0.004; duration x drug interaction: p = 0.01) and VS (effect of drug: F(1,44) = 
4.9, p = 0.03; effect of duration: p = 0.04; duration x drug interaction: p = 0.03) but failed to 
alter D1 receptor density in the FC and DS (Fig. 2D). In summary, similar to TH and VMAT2 
the effect of chronic (but not acute) MPH administration on D1 receptor expression was only 




In the first part of this study, we show that MPH increases DAT expression in striatum and 
that such effect was dependent on both duration of treatment and brain hemisphere 
investigated. This study also provides new evidence that chronic (2 mg/kg, twice daily for 2 
weeks) but not acute MPH administration has a preferential action on key catecholamine 
protein targets: NET, VMAT2, TH and D1 receptors in the PCx and VS over the FC and DS. 
 
DAT is the main target of MPH and abnormalities of this transporter have been widely 
associated with ADHD (Dougherty et al., 1999;Volkow et al., 2007;Del Campo et al., 2011). 
However, the direction of DAT abnormality in ADHD is still under intense debate with some 
studies suggesting increased striatal DAT expression in individuals diagnosed with ADHD 
(Dougherty et al., 1999;Cheon et al., 2003), while other reports indicate decreased DAT 
levels in the striatum (Volkow et al., 2007;Volkow et al., 2009;Hesse et al., 2009), and yet 
some others report no differences in DAT density betwe n ADHD patients and healthy 














in studies using animal models of ADHD. Specifically, studies using the spontaneously 
hypertensive rat (SHR), a validated model for some f the symptoms of ADHD (Sagvolden 
and Johansen, 2012), have shown increased striatal DAT gene and protein expression, as well 
as reduced DAT expression in cortical and striatal reas compared to normal rats (Roessner et 
al., 2010;Simchon et al., 2010;Somkuwar et al., 2013). It is however, possible that the 
selection of different reference strains used as control animals could explain these differences 
(Sagvolden et al., 2009). Considering the inconsistency of DAT expression using animal 
models of ADHD and the lack of a defined pathogenesis and reliable biomarkers for ADHD 
(Faraone et al., 2014), this study used normal juvenile rats to investigate the action of MPH 
on protein markers for dopamine and noradrenaline fu ction. While the diagnosis of ADHD 
is acknowledged in both children and adults, age-dependent action of MPH has been 
identified in both human and animal studies (Schrantee et al., 2016). The aim of the current 
study was to investigate the action of MPH on the still developing brain. Hence, we used rats 
at the developmental stages of PND 25 and 39 which could be approximated to human ages 
of 2-4 years and 12-13 years respectively (Andreollo et al., 2012).     
 
The findings of the present study that chronic MPH increases striatal DAT expression (Fig. 1) 
suggest that the previous findings showing overexprssed levels of DAT in ADHD patients 
could be due to the effects of long-term MPH treatment rather than an assumed pathology of 
the condition itself. Indeed, the present findings on DAT is consistent with a previous clinical 
study which demonstrated that chronic exposure to MPH increased ventral striatal DAT 
density in ADHD patients (Wang et al., 2013). MPH blocks DAT, which increases the 
extracellular levels of dopamine (Berridge et al., 2006;Kuczenski and Segal, 2002). However, 
presynaptic DAT density has in turn been shown to be regulated by extracellular dopamine 
levels, with DAT density declining when extracellular dopamine level is low and increasing 














increased DAT density observed in the VS and DS of this study, following chronic MPH 
injections reflects an adaptive response to prolonged MPH treatment. Indeed, several studies 
have previously shown that both acute and chronic MPH treatment increase extracellular 
dopamine levels in VS and DS, as well as in other brain areas such as the cortex and midbrain 
(Calipari et al., 2014;Calipari and Jones, 2014;Koda et al., 2010;Wagner et al., 2009;Berridge 
et al., 2006;Kuczenski and Segal, 2002;Volkow et al., 2001). A sustained MPH-induced 
increase of extracellular dopamine, in spite of an upregulation of DAT the main target of the 
drug, could partly be explained in the light of a recent finding that chronic MPH 
administration to rats at a similar age (PND 28) as used in the present study (PND 25) causes 
a partial down-regulation of D2 auto-receptor function in the ventral tegmental area (Di 
Miceli et al., 2018). The idea of a neuroadaptive increase of DAT is however, consistent with 
previous studies which have shown that MPH may be effective in the short-term but that its 
long-term clinical effectiveness may be limited, as larger doses may be required to ensure 
clinical effectiveness (Hazell, 2011;Wang et al., 2013). In line with MPH causing 
neuroadaptive changes, we have recently shown that chronic administration of MPH to young 
rats enhances the expression of genes and proteins m diating neuroplasticity (Quansah et al., 
2017b). In addition, chronic MPH also increased NET density in the VS (Fig. 2A) and it is 
conceivable that similar to striatal DAT, the levels of NET could also vary as a function of its 
substrate noradrenaline. It is however, worth noting hat additional factors (other than MPH-
induced elevation of extracellular catecholamine lev ls) may also underlie the increased 
expression of DAT and NET detected in the present study. Thus, considering the high affinity 
for MPH on the DAT and NET, as well as studies suggesting that these transporters exhibit 
some of the functional qualities similar to G-protein- coupled receptors, the direct binding of 
MPH to DAT or NET may also contribute to the upregulation of their expression (Schmitt et 















Notably, the MPH-induced upregulation of DAT following chronic administration showed a 
hemispheric effect in the DS but not in the VS. In the DS, chronic MPH only increased DAT 
levels in the left side (Fig. 1). This left hemisphere effect of MPH in the DS is not supportive 
of clinical reports showing greater right hemisphere abnormalities in ADHD (Heilman and 
Van Den Abell, 1980;Heilman et al., 1986;Castellanos et al., 1996;Vance et al., 2007). 
However, in support of our preclinical study, a previous clinical investigation has also 
demonstrated more pronounced left hemisphere (i.e. left cortical and left striatal) effect of 
MPH on several brain neurochemicals in ADHD children (Benamor, 2014).  
 
The elevated density of TH in the PCx and VS (Fig. 2B) suggests an enhanced catecholamine 
synthesis following chronic but not acute MPH administration. Similar to our findings on TH 
in the FC and DS, a previous study using normal and SHR rats, failed to show MPH-induced 
changes in TH levels in FC (Pardey et al., 2012). In contrast, an additional study using 
normal rats and beginning the chronic MPH treatment at an earlier stage of development 
(PND 7)  as well as with a longer duration (4 weeks) compared to the present study (PND 25 
and 2 weeks respectively), detected increases in TH-immunoreactive fibre density in FC 
(Gray et al., 2007). The discrepancies between these studies highlight the influence of the 
developmental stage on the action of MPH. Thus, our previous studies have shown that MPH 
induced effects on gene expression as well as firing of prefrontal cortex neurons are both age 
dependent (Banerjee et al., 2007; Gronier et al., 2010). In addition, and more recently Di 
Miceli et al showed; decreased D2 auto-receptor function in young rats (PND 28) chronically 
treated with MPH but not in adolescent rats (PND 42), (Di Miceli et al., 2018). In support, of 
an increased TH activity as shown here in the PCx and VS, the present study also shows 
increased levels of VMAT2 in these two brain regions (Fig. 2C). In this respect, previous 














VMAT2, as well as promoting cellular redistribution f VMAT2 from the plasma membrane 
to the subcellular vesicular fraction (Sandoval et al., 2002). Together with the results of the 
present study, this suggests that chronic MPH treatm n  increases synthesis and vesicular 
storage of dopamine and noradrenaline in the PCx and VS. In this respect, it is interesting to 
note that we have shown in a recent study that a single MPH injection to adolescent rats 
increases levels of the catecholamine precursor tyrsine in tissue samples of the cerebrum 
(Quansah et al., 2017a). In the FC, we also measured an increase of VMAT2 this effect 
however, did not coincide with an enhanced expression of TH. Given that the magnitude of 
MPH-induced increase of locomotor activity and extracellular catecholamine levels following 
chronic administration has been shown to be closely matched by acute administration (Koda 
et al., 2010;Kuczenski and Segal, 2002), simultaneous increases of TH, VMAT2 and tyrosine 
could compensate for the continuous blockade of DAT and NET (Fig. 1 and 2A) and thereby 
help to sustain high levels of the two catecholamines i  the synaptic cleft. 
 
Psychostimulant induced activation of the dopamine D1 receptor is associated with the 
reduction of ADHD symptoms, including hyperactivity and cognitive defects (Gamo et al., 
2010;Napolitano et al., 2010;Wu et al., 2012). In the present study, chronic MPH increased 
D1 receptor density in the PCx and VS suggesting that the reatment increases D1 receptor-
mediated dopamine signalling in these brain areas. Dy function of: cingulate, frontal and 
parietal cortical regions have been implicated in the pathophysiology and symptoms of 
ADHD including impairment of cognitive performance (Bush, 2011). In this context, the 
enhancement of D1 receptor expression in the PCx shown here could contribute to a sustained 
therapeutic action following long-term MPH treatment (Mehta et al., 2000). The potential 
beneficial action of enhanced D1 function in the VS is however questionable, as D1 receptor 
activation in this part of the brain is known to stimulate reward-related behaviour following 














(Self, 2014).  Moreover, the finding of this study that MPH-induced elevation of protein 
targets for catecholamine function was particularly marked in VS and PCx, two brain areas 
implicated in arousal and attention is supportive of the “arousal theory of  ADHD” (Gutierrez 
et al., 2011). A theory which states that ADHD patien s have abnormally low arousal (James 
et al., 2016). Further when considering the role of catecholamines in promoting arousal 
(Berridge, 2006) the findings of the present study could help to explain the underlying 




In summary, the results of this study highlight the possibility that chronic MPH 
administration has the potential to induce plasticity of the developing brain. Specifically, the 
present study shows that chronic MPH administration to young animals induces marked 
changes in the expression of some key proteins mediating catecholamine function. Some of 
these changes were particularly prominent in the PCx and the VS. Considering the relatively 
small number of rats (n=6 rats/group) and the limited time after cessation of MPH treatment 
(24 hours) further studies should be performed to evaluate the clinical significance of our 
findings. Notably, we report upregulations of DAT and NET secondary to long-term MPH 
treatment in young animals. It is possibly that this effect contributes to the occasional need 
for larger doses of the drug during long-term treatment in order to obtain therapeutic efficacy.      
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Figure 1. Effect of MPH treatment on DAT protein density in the left (LB) and right (RB) 
hemispheres of ventral striatum (VS) and dorsal striatum (DS) of adolescent rats. Values 
represent percentage ± S.E.M (n=6 rats/group); *p < 0.05, **p < 0.01, ***p < 0.001. 
Representative blots are shown to the right of the plot.    
 
Figure 2. Effect of MPH treatment on: (A) Noradrenaline transporter [NET], (B) Tyrosine 
hydroxylase [TH], (C) Vesicular monoamine transporter [VMAT2], and (D) D1 receptor 
densities in the frontal cortex [FC], parietal cortex [PCx], ventral striatum [VS], and dorsal 
striatum [DS] of adolescent rats. Representative blots are shown to the right of each plot. 
Values represent percentage ± S.E.M (n=6 rats/group but 12 data points/group: 2 data points 
from each animal, one from the left and one from right side); *p < 0.05, **p < 0.01, ***p < 








































































































































































































































• Here we show new evidence that chronic administration of the anti ADHD drug 
methylphenidate when given to young rats preferentially alters key catecholamine 
targets in parietal cortex and ventral striatum over dorsal striatum and frontal cortex. 
   
• The data also demonstrate that the effects of methylphenidate on key catecholamine 
targets depend on duration of treatment. 
 
• In conclusion, these findings provide novel insights into the mechanism of action by 
MPH in the treatment of ADHD and further suggest that the long-term effectiveness 
of the stimulant drug could be limited. 
 
 
 
 
 
